

Supplementary Table S5. Baseline characteristics according to baseline frequency of PD1+CD8+ T cells

	<i>PD1+CD8+</i> <i>high (≥ 6.8%)</i> n=34		<i>PD1+CD8+</i> <i>low (< 6.8%)</i> n=34		p value*
Age (years)					0.467
< 65	16	(47.1%)	19	(55.9%)	
≥ 65	18	(52.9%)	15	(44.1%)	
Sex					0.012
Male	30	(88.2%)	20	(58.8%)	
Female	4	(11.8%)	14	(41.2%)	
ECOG PS					1.000
0,1	32	(94.1%)	32	(94.1%)	
2	2	(5.9%)	2	(5.9%)	
Differentiation					0.793
Well to moderate	10	(29.4%)	11	(32.4%)	
Poor	24	(70.6%)	23	(67.6%)	
HER2					0.673
Positive	4	(11.8%)	2	(5.9%)	
Negative	30	(88.2%)	32	(94.1%)	
Disease status					0.709
Locally advanced	5	(14.7%)	3	(8.8%)	
Metastatic	29	(85.3%)	31	(91.2%)	
Peritoneal seeding					0.145
Yes	15	(44.1%)	21	(61.8%)	
No	19	(55.9%)	13	(38.2%)	
No. of metastatic sites					0.442
≥ 2	10	(29.4%)	13	(38.2%)	
< 2	24	(70.6%)	21	(61.8%)	
CEA (ng/mL)					1.000
> 5	12	(35.3%)	12	(35.3%)	
≤ 5	22	(64.7%)	22	(64.7%)	
CA 19-9 (U/mL)					0.798
> 37	12	(35.3%)	11	(32.4%)	
≤ 37	22	(64.7%)	23	(67.6%)	
Tissue PD-L1					0.891
CPS ≥ 10	15	(44.1%)	15	(44.1%)	
CPS < 10	16	(47.1%)	17	(50.0%)	
Undetermined	3	(8.8%)	2	(5.9%)	

* P value from chi-squared tests or Fisher's exact tests for categorical variables. Data are represented as n (%). ECOG PS, Eastern Cooperative Oncology Group Performance Status; HER2, human epidermal growth factor receptor 2; CEA, carcinoembryonic antigen; CA 19-9, Cancer antigen 19-9; PD-L1, programmed death ligand 1; CPS, combined positive score.